

Gregory J Gores

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8689453/gregory-j-gores-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

457
papers

53,176
citations

130
h-index

219
g-index

496
ext. papers

61,337
ext. citations

7.8
avg, IF

7.95
L-index

#	Paper	IF	Citations
457	Design and endpoints of clinical trials in hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 698-711	9.7	1360
456	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16018	51.1	1274
455	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 589-604	24.2	1209
454	Cholangiocarcinoma. <i>Lancet, The</i> , 2014 , 383, 2168-79	4.0	981
453	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , 2014 , 63, 844-55	19.2	953
452	Mechanisms of hepatotoxicity. <i>Toxicological Sciences</i> , 2002 , 65, 166-76	4.4	877
451	Diagnosis and management of primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 51, 660-78	11.2	837
450	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 1268-89	13.4	815
449	Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. <i>Gastroenterology</i> , 2003 , 125, 437-43	13.3	803
448	Biliary tract cancers. <i>New England Journal of Medicine</i> , 1999 , 341, 1368-78	59.2	802
447	Pathogenesis, diagnosis, and management of cholangiocarcinoma. <i>Gastroenterology</i> , 2013 , 145, 1215-29	13.3	747
446	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. <i>Lancet Oncology, The</i> , 2012 , 13, e11-22	21.7	701
445	Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. <i>Hepatology</i> , 2004 , 40, 185-94	11.2	619
444	Cholangiocarcinoma - evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 95-111	19.4	599
443	Lysosomes in cell death. <i>Oncogene</i> , 2004 , 23, 2881-90	9.2	578
442	Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1127-37	15.9	566
441	Apoptosis and necrosis in the liver: a tale of two deaths?. <i>Hepatology</i> , 2006 , 43, S31-44	11.2	537

440	Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. <i>Hepatology</i> , 2008 , 48, 308-21	11.2	536
439	Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2006 , 281, 12093-101	5.4	510
438	The role of proteases during apoptosis. <i>FASEB Journal</i> , 1996 , 10, 587-97	0.9	491
437	Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. <i>Annals of Surgery</i> , 2005 , 242, 451-8; discussion 458-61	7.8	476
436	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013 , 45, 1470-1473	36.3	464
435	Clinical diagnosis and staging of cholangiocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 512-22	24.2	446
434	Life and death by death receptors. <i>FASEB Journal</i> , 2009 , 23, 1625-37	0.9	443
433	Apoptosis: the nexus of liver injury and fibrosis. <i>Hepatology</i> , 2004 , 39, 273-8	11.2	433
432	Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. <i>Journal of Clinical Investigation</i> , 1999 , 103, 137-45	15.9	425
431	Cellular and molecular mechanisms of liver injury. <i>Gastroenterology</i> , 2008 , 134, 1641-54	13.3	420
430	Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. <i>Transplantation</i> , 1999 , 68, 1517-25	1.8	417
429	Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. <i>Seminars in Liver Disease</i> , 2008 , 28, 360-9	7.3	393
428	Cholangiocarcinoma. <i>Gastroenterology</i> , 2005 , 128, 1655-67	13.3	375
427	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
426	Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. <i>Gastroenterology</i> , 2012 , 143, 88-98.e3; quiz e14	13.3	353
425	Ischemic-type biliary complications after orthotopic liver transplantation. <i>Hepatology</i> , 1992 , 16, 49-53	11.2	348
424	Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. <i>Hepatology</i> , 2003 , 38, 1188-98	11.2	347
423	Hepatocyte death: a clear and present danger. <i>Physiological Reviews</i> , 2010 , 90, 1165-94	47.9	342

422	Liver cell necrosis: cellular mechanisms and clinical implications. <i>Gastroenterology</i> , 1995 , 108, 252-75	13.3	327
421	Apoptotic body engulfment by a human stellate cell line is profibrogenic. <i>Laboratory Investigation</i> , 2003 , 83, 655-63	5.9	316
420	The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2000 , 95, 204-7	0.7	315
419	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3994-4005	2.2	306
418	Cholangiocarcinomas can originate from hepatocytes in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2911-5	15.9	297
417	A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1675-81	0.7	295
416	Ursodeoxycholic acid Pmechanisms of action and clinical use in hepatobiliary disordersP. <i>Journal of Hepatology</i> , 2001 , 35, 134-46	13.4	292
415	Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. <i>Gastroenterology</i> , 2013 , 145, 521-36	13.3	290
414	Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. <i>Liver Transplantation</i> , 2000 , 6, 309-16	4.5	283
413	Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, G825-34	5.1	275
412	Recurrence of primary sclerosing cholangitis following liver transplantation. <i>Hepatology</i> , 1999 , 29, 1050-61.2	6.2	275
411	Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. <i>Hepatology</i> , 1999 , 30, 1121-7	11.2	274
410	Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. <i>Journal of Hepatology</i> , 2003 , 39, 978-83	13.4	269
409	Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. <i>Gastroenterology</i> , 1999 , 117, 669-77	13.3	265
408	Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. <i>Gastroenterology</i> , 2002 , 123, 1323-30	13.3	256
407	Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. <i>Gastroenterology</i> , 2016 , 150, 956-67	13.3	255
406	Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. <i>Gastroenterology</i> , 2006 , 131, 1064-72	13.3	252
405	The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1734-40	4	243

404	Use of fatty donor liver is associated with diminished early patient and graft survival. <i>Transplantation</i> , 1996 , 62, 1246-51	1.8	243
403	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. <i>Oncogene</i> , 2005 , 24, 6861-9	9.2	240
402	The isolated perfused rat liver: conceptual and practical considerations. <i>Hepatology</i> , 1986 , 6, 511-7	11.2	239
401	Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. <i>Journal of Hepatology</i> , 2001 , 34, 248-53	13.4	237
400	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. <i>Hepatology</i> , 2009 , 49, 1595-601	11.2	225
399	Cholangiocarcinoma: modern advances in understanding a deadly old disease. <i>Journal of Hepatology</i> , 2006 , 45, 856-67	13.4	222
398	Hepatocellular carcinoma: molecular pathways and new therapeutic targets. <i>Seminars in Liver Disease</i> , 2005 , 25, 212-25	7.3	222
397	Cholangiocarcinoma: current concepts and insights. <i>Hepatology</i> , 2003 , 37, 961-9	11.2	214
396	Apoptosis and necrosis in the liver. <i>Comprehensive Physiology</i> , 2013 , 3, 977-1010	7.7	212
395	Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. <i>Journal of Biological Chemistry</i> , 2002 , 277, 44236-43	5.4	209
394	Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 281, G626-34	5.1	206
393	Cancer surveillance in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2011 , 54, 1842-52	11.2	204
392	New staging system and a registry for perihilar cholangiocarcinoma. <i>Hepatology</i> , 2011 , 53, 1363-71	11.2	202
391	Primary sclerosing cholangitis: summary of a workshop. <i>Hepatology</i> , 2006 , 44, 746-64	11.2	202
390	Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. <i>Cancer Research</i> , 2004 , 64, 3517-24	10.1	197
389	Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. <i>Hepatology</i> , 2005 , 42, 1329-38	11.2	195
388	Classification, diagnosis, and management of cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 13-21.e1; quiz e3-4	6.9	194
387	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. <i>Hepatology</i> , 2008 , 47, 1495-503	11.2	192

386	Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. <i>Hepatology</i> , 1993 , 17, 605-9	11.2	192
385	The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 1191-6	4.7	191
384	The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 953-66	7.9	189
383	Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. <i>Hepatology</i> , 1999 , 30, 1128-33	11.2	189
382	Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2008 , 12, 131-50, ix	4.6	188
381	Liver transplantation for cholangiocarcinoma. <i>Transplant International</i> , 2010 , 23, 692-7	3	184
380	Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. <i>Transplantation</i> , 1999 , 68, 89-96	1.8	183
379	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. <i>Gastroenterology</i> , 2005 , 128, 2054-65	13.3	182
378	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014 , 45, 1630-8	3.7	179
377	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. <i>Gastroenterology</i> , 2007 , 132, 384-96	13.3	179
376	Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. <i>Hepatology</i> , 2003 , 37, 87-95	11.2	179
375	Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. <i>Journal of Hepatology</i> , 2010 , 52, 586-93	13.4	177
374	Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. <i>American Journal of Pathology</i> , 2001 , 159, 2045-54	5.8	177
373	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015 , 62, S144-56	13.4	175
372	Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. <i>Human Pathology</i> , 2012 , 43, 1552-8	3.7	175
371	Liver transplantation for unresectable perihilar cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004 , 24, 201-7	7.3	175
370	Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. <i>Gastroenterology</i> , 2001 , 120, 190-9	13.3	175
369	Death receptors in liver biology and pathobiology. <i>Hepatology</i> , 1999 , 29, 1-4	11.2	173

368	Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. <i>Hepatology</i> , 1990 , 11, 690-8	11.2	171
367	Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Mayo Clinic Proceedings</i> , 1993 , 68, 874-9	6.4	170
366	Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. <i>Liver Transplantation</i> , 2004 , 10, 449-55	4.5	169
365	Apoptosis and liver disease. <i>American Journal of Medicine</i> , 2000 , 108, 567-74	2.4	168
364	CHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. <i>Hepatology</i> , 2018 , 68, 113-126	11.2	164
363	Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. <i>Transplantation</i> , 2006 , 82, 1703-7	1.8	163
362	Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. <i>Hpb</i> , 2011 , 13, 356-60	3.8	162
361	A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 214-9	6.9	162
360	Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 152-159	15.9	162
359	Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. <i>Gut</i> , 2007 , 56, 1124-31	19.2	161
358	Apoptosis and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009 , 49, 871-9	11.2	158
357	The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. <i>Journal of Biological Chemistry</i> , 2000 , 275, 20210-6	5.4	157
356	JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 26591-602	5.4	156
355	Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2007 , 282, 27141-27154	5.4	156
354	Cholangiocyte pathobiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 269-281	24.2	155
353	Apoptosis in alcoholic and nonalcoholic steatohepatitis. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 3093-9		155
352	Death receptor-mediated apoptosis and the liver. <i>Journal of Hepatology</i> , 2002 , 37, 400-10	13.4	155
351	Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1843-52	15.9	154

350	A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. <i>Gastroenterology</i> , 2009 , 136, 2180-6	13.3	151
349	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. <i>Gastroenterology</i> , 2002 , 122, 985-93	13.3	149
348	Apoptosis in cancer: cause and cure. <i>BioEssays</i> , 2000 , 22, 1007-17	4.1	149
347	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017 , 66, 1125-1143	11.2	148
346	Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 278, G992-9	5.1	147
345	CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, G236-43	5.1	145
344	Mitochondrial injury and caspase activation by the local anesthetic lidocaine. <i>Anesthesiology</i> , 2004 , 101, 1184-94	4.3	140
343	Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. <i>American Journal of Physiology - Renal Physiology</i> , 2002 , 283, G947-56	5.1	140
342	The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. <i>Journal of Biological Chemistry</i> , 2001 , 276, 38610-8	5.4	138
341	Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. <i>Gut</i> , 2018 , 67, 963-972	19.2	137
340	Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, G77-84	5.1	136
339	Dysregulation of apoptosis as a mechanism of liver disease: an overview. <i>Seminars in Liver Disease</i> , 1998 , 18, 105-14	7.3	135
338	The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. <i>Hepatology</i> , 1999 , 30, 1490-7	11.2	135
337	Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. <i>Journal of Lipid Research</i> , 2016 , 57, 1758-1770	6.3	135
336	Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010 , 51, 174-80	11.2	134
335	Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. <i>Journal of Hepatology</i> , 2016 , 64, 651-60	13.4	133
334	Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G1339-46	5.1	133
333	Mechanisms of lipotoxicity in NAFLD and clinical implications. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011 , 53, 131-40	2.8	131

332	Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3241-51	15.9	131
331	Apoptosis as a mechanism for liver disease progression. <i>Seminars in Liver Disease</i> , 2010 , 30, 402-10	7.3	130
330	In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1138-42	0.7	130
329	Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. <i>Hepatology</i> , 2016 , 63, 731-44	11.2	129
328	Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflamm. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1325-36	4	124
327	Extracellular vesicles in liver pathobiology: Small particles with big impact. <i>Hepatology</i> , 2016 , 64, 2219-2233	13.3	123
326	Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. <i>Liver Transplantation</i> , 2006 , 12, 448-56	4.5	123
325	Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. <i>Cancer Research</i> , 2013 , 73, 897-907	10.1	121
324	EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2008 , 67, 438-43	5.2	121
323	Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. <i>Hepatology</i> , 1987 , 7, 889-92	11.2	121
322	Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 17-27	7.9	120
321	Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G129-36	5.1	119
320	Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. <i>American Journal of Physiology - Renal Physiology</i> , 2003 , 285, G31-6	5.1	116
319	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. <i>Human Pathology</i> , 2013 , 44, 1216-22	3.7	114
318	Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. <i>Hepatology</i> , 2011 , 54, 2076-88	11.2	114
317	Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. <i>Transplantation</i> , 1991 , 51, 959-65	1.8	114
316	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016 , 65, 859-860	13.4	114
315	COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. <i>Hepatology</i> , 2002 , 35, 552-9	11.2	111

314	Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. <i>Hepatology</i> , 1999 , 29, 1037-43	11.2	109
313	Emerging molecular therapeutic targets for cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 632-644	13.4	105
312	Proteasome inhibition induces hepatic stellate cell apoptosis. <i>Hepatology</i> , 2006 , 43, 335-44	11.2	105
311	Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. <i>Journal of Biological Chemistry</i> , 2007 , 282, 28960-28970	5.4	103
310	Pathogenesis, diagnosis, and treatment of alcoholic liver disease. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 1021-9	6.9	102
309	Mechanisms of liver injury: an overview. <i>Current Molecular Medicine</i> , 2003 , 3, 483-90	2.5	101
308	Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2004 , 41, 808-14	13.4	101
307	Endoscopic application of photodynamic therapy for cholangiocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2001 , 53, 500-4	5.2	101
306	Primary sclerosing cholangitis and cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2006 , 26, 42-51	7.3	100
305	Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. <i>Hepatology</i> , 2001 , 33, 1432-40	11.2	99
304	Alcoholic hepatitis: current challenges and future directions. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 555-64; quiz e31-2	6.9	97
303	Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. <i>Gastroenterology</i> , 2005 , 128, 1354-68	13.3	97
302	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 103-111	18.8	96
301	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. <i>Hepatology</i> , 2012 , 56, 972-81	11.2	96
300	Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 1999 , 5, 192-9		95
299	Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. <i>Hepatology</i> , 2019 , 69, 1803-1815	11.2	95
298	Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. <i>Hepatology</i> , 2013 , 57, 648-55	11.2	94
297	Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2003 , 284, G734-8	5.1	94

296	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016 , 63, 1357-67	11.2	94
295	Death receptor 5 signaling promotes hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2011 , 286, 39336-48	5.4	93
294	Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. <i>Hepatology</i> , 2009 , 50, 1861-70	11.2	93
293	Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. <i>Journal of Biological Chemistry</i> , 2003 , 278, 454-61	5.4	93
292	Cathepsins as effector proteases in hepatocyte apoptosis. <i>Cell Biochemistry and Biophysics</i> , 1999 , 30, 71-88	3.2	93
291	Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. <i>Cancer Research</i> , 2002 , 62, 1648-53	10.1	93
290	Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1998 , 1366, 167-75	4.6	90
289	Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. <i>Journal of Biological Chemistry</i> , 2007 , 282, 18407-18417	5.4	89
288	Cholangiocarcinoma: molecular pathways and therapeutic opportunities. <i>Seminars in Liver Disease</i> , 2014 , 34, 456-64	7.3	88
287	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. <i>Hepatology</i> , 2015 , 61, 1627-42	11.2	87
286	MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. <i>Hepatology</i> , 2011 , 54, 2089-98	11.2	86
285	Mortality and hospital utilization for hepatocellular carcinoma in the United States. <i>Gastroenterology</i> , 2005 , 129, 486-93	13.3	86
284	Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. <i>Hepatology</i> , 2014 , 59, 2397-402	11.2	85
283	The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. <i>Liver Transplantation</i> , 2003 , 9, 278-84	4.5	85
282	p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. <i>Gastroenterology</i> , 2002 , 123, 1090-8	13.3	85
281	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 353-363	13.4	83
280	The mTOR pathway in hepatic malignancies. <i>Hepatology</i> , 2013 , 58, 810-8	11.2	83
279	Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2023-8	0.7	83

278	Management of liver adenomatosis: results with a conservative surgical approach. <i>Liver Transplantation</i> , 1998 , 4, 388-98		83
277	TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. <i>American Journal of Physiology - Renal Physiology</i> , 2004 , 287, G436-43	5.1	83
276	Early detection and treatment of cholangiocarcinoma. <i>Liver Transplantation</i> , 2000 , 6, S30-4	4.5	83
275	An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. <i>Gastroenterology</i> , 2015 , 149, 1813-1824.e1	13.3	81
274	Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2152-65	6.9	80
273	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 767-775.e3	6.9	78
272	Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. <i>Liver Transplantation</i> , 2007 , 13, 1372-81	4.5	78
271	Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 303, 461-7	4.7	75
270	The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. <i>Hepatology</i> , 2018 , 67, 1284-1302	11.2	74
269	Mechanisms and clinical implications of hepatocyte lipoapoptosis. <i>Clinical Lipidology</i> , 2010 , 5, 71-85		74
268	The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. <i>Gastroenterology</i> , 2001 , 120, 1810-7	13.3	74
267	Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. <i>Hepatology</i> , 1994 , 19, 925-932	11.2	74
266	TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. <i>Journal of Hepatology</i> , 2015 , 62, 1156-63	13.4	73
265	Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. <i>Journal of Hepatology</i> , 2003 , 39, 414-20	13.4	72
264	Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. <i>Hepatology</i> , 2004 , 39, 732-8	11.2	71
263	Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. <i>Journal of Hepatology</i> , 1997 , 27, 512-6	13.4	70
262	TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. <i>Hepatology</i> , 2008 , 47, 1317-30	11.2	70
261	Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2) mice. <i>Hepatology</i> , 2018 , 67, 247-259	11.2	70

260	Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. <i>Gastroenterology</i> , 2005 , 129, 269-84	13.3	69
259	Is TRAIL hepatotoxic?. <i>Hepatology</i> , 2001 , 34, 3-6	11.2	69
258	Transplantation for hilar cholangiocarcinoma. <i>Liver Transplantation</i> , 2004 , 10, S65-8	4.5	68
257	NF-kappaB is activated in cholestasis and functions to reduce liver injury. <i>American Journal of Pathology</i> , 2001 , 158, 967-75	5.8	68
256	Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 152-9	15.9	68
255	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012 , 56, 614-21	11.2	67
254	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006 , 12, S95-7	4.5	66
253	Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. <i>Journal of Hepatology</i> , 2011 , 54, 765-72	13.4	65
252	Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. <i>Genes and Development</i> , 2012 , 26, 305-11	12.6	65
251	Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005 , 20, 415-20	4	65
250	Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 780-6	5.1	64
249	Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2013 , 8, e70599	3.7	64
248	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 531-538	4	64
247	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020 , 71, 907-916	11.2	64
246	Hepatology: a home for hepatocellular cancer publications. <i>Hepatology</i> , 2009 , 50, 1-2	11.2	63
245	A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. <i>Journal of Lipid Research</i> , 2011 , 52, 1517-25	6.3	63
244	Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. <i>American Journal of Clinical Pathology</i> , 2007 , 128, 272-9	1.9	63
243	Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. <i>Journal of Hepatology</i> , 2018 , 69, 676-686	13.4	62

242	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. <i>Cancer Research</i> , 2002 , 62, 6500-5	10.1	61
241	A new clinically based staging system for perihilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1881-90	0.7	60
240	Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2005 , 11, 1207-13	4.5	60
239	Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 599-605	13.4	59
238	Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. <i>Gastroenterology</i> , 2009 , 136, 2365-2376.e1-7	13.3	59
237	A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. <i>Journal of Biological Chemistry</i> , 2016 , 291, 8031-47	5.4	59
236	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 72-83	13.4	57
235	Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?. <i>Journal of the American College of Surgeons</i> , 2012 , 215, 31-8; discussion 38-40	4.4	57
234	Performance of magnetic resonance elastography in primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1184-90	4	57
233	Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. <i>American Journal of Gastroenterology</i> , 2001 , 96, 1164-9	0.7	56
232	Liver transplantation for perihilar cholangiocarcinoma. <i>Digestive Diseases</i> , 2013 , 31, 126-9	3.2	55
231	Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. <i>Cancer Cytopathology</i> , 2013 , 121, 708-17	3.9	55
230	Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 56-65	4.7	54
229	Endoscopic ultrasound staging of cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2012 , 28, 244-52	3	53
228	Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1256-62	0.7	53
227	Transplantation for cholangiocarcinoma: when and for whom?. <i>Surgical Oncology Clinics of North America</i> , 2009 , 18, 325-37, ix	2.7	53
226	cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. <i>Journal of Biological Chemistry</i> , 2003 , 278, 26831-7	5.4	53
225	Death receptor-mediated liver injury. <i>Seminars in Liver Disease</i> , 2007 , 27, 327-38	7.3	52

224	Cholangiocarcinoma: is transplantation an option? For whom?. <i>Journal of Hepatology</i> , 2007 , 47, 455-9	13.4	52
223	Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. <i>Hepatology</i> , 2016 , 63, 1900-13	11.2	51
222	Treatment options for hepatobiliary and pancreatic cancer. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 628-37	6.4	51
221	Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2002 , 11, 909-21	2.7	51
220	Efflux of protons from acidic vesicles contributes to cytosolic acidification of hepatocytes during ATP depletion. <i>Hepatology</i> , 1991 , 14, 626-633	11.2	50
219	Therapeutic targeting of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, G209-15	5.1	48
218	A hedgehog survival pathway in RndeadPipotoxic hepatocytes. <i>Journal of Hepatology</i> , 2012 , 57, 844-51	13.4	48
217	A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. <i>Hepatology</i> , 2010 , 52, 550-61	11.2	48
216	Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies?. <i>Surgery</i> , 2006 , 140, 331-4	3.6	48
215	Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. <i>American Journal of Physiology - Renal Physiology</i> , 2004 , 287, G88-95	5.1	47
214	An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. <i>Hepatology</i> , 2020 , 72, 441-453	11.2	47
213	Primary Sclerosing Cholangitis Risk Estimate Tool (PRESto) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. <i>Hepatology</i> , 2020 , 71, 214-224	11.2	47
212	A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. <i>Cancer Research</i> , 2010 , 70, 1960-9	10.1	46
211	Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 299-309	0.7	45
210	Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Gastroenterology</i> , 2004 , 126, 849-58	13.3	44
209	Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. <i>PLoS ONE</i> , 2012 , 7, e45606	3.7	44
208	Targeting cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 1454-1460	6.9	43
207	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1573-1580	0.7	43

206	YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. <i>Molecular Cancer Research</i> , 2018 , 16, 1556-1567	6.6	43
205	Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. <i>Hepatology</i> , 2006 , 44, 252-62	11.2	43
204	Mitochondrial dysfunction during anoxia/reoxygenation injury of liver sinusoidal endothelial cells. <i>Hepatology</i> , 1994 , 20, 177-185	11.2	43
203	Acidosis protects against lethal oxidative injury of liver sinusoidal endothelial cells. <i>Hepatology</i> , 1991 , 14, 150-7	11.2	42
202	Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. <i>Journal of Surgical Oncology</i> , 2016 , 114, 475-82	2.8	42
201	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). <i>Journal of Biological Chemistry</i> , 2012 , 287, 24427-37	5.4	41
200	Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. <i>Journal of Cellular Physiology</i> , 1996 , 167, 434-42	7	41
199	A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1792-6	0.7	40
198	Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. <i>Journal of Biological Chemistry</i> , 2014 , 289, 22835-22849	5.4	39
197	Mesothelin as a potential therapeutic target in human cholangiocarcinoma. <i>Journal of Cancer</i> , 2010 , 1, 141-9	4.5	39
196	Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. <i>American Journal of Physiology - Renal Physiology</i> , 1999 , 277, G599-608	5.1	39
195	Lytic cell death in metabolic liver disease. <i>Journal of Hepatology</i> , 2020 , 73, 394-408	13.4	39
194	Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. <i>Liver International</i> , 2014 , 34, 427-37	7.9	38
193	Hepatocyte transplantation in acute liver failure: a new therapeutic option for the next millennium?. <i>Liver Transplantation</i> , 2000 , 6, 41-3	4.5	38
192	Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. <i>Hepatology</i> , 1999 , 30, 811-5	11.2	38
191	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019 , 1, 297-311	10.3	37
190	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2339-47	6.1	37
189	Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 824-836	4.7	34

188	Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. <i>Experimental Cell Research</i> , 2011 , 317, 107-16	4.2	34
187	Mcl-1 degradation during hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 30039-48	5.4	34
186	Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S15-9	4.5	34
185	Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 645-7	24.2	33
184	Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes. <i>Gastroenterology</i> , 1992 , 102, 1030-8	13.3	33
183	Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. <i>Hepatology</i> , 2017 , 65, 1249-1266	11.2	32
182	Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. <i>Hepatology</i> , 2013 , 58, 1362-74	11.2	32
181	cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, G1337-46	5.1	32
180	Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 510-8	6.7	32
179	A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2017 , 312, G666-G680	5.1	31
178	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018 , 38, 160-169	7.3	31
177	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015 , 31, 264-8	3	31
176	Molecular pathogenesis of cholangiocarcinoma. <i>Digestive Diseases</i> , 2014 , 32, 564-9	3.2	31
175	Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma. <i>Endoscopy</i> , 2015 , 47, 878-83	3.4	30
174	Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. <i>Hepatology</i> , 2007 , 46, 906-11	11.2	30
173	Emerging drugs for hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 469-87	3.7	30
172	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. <i>JCI Insight</i> , 2017 , 2,	9.9	30
171	YAP-associated chromosomal instability and cholangiocarcinoma in mice. <i>Oncotarget</i> , 2018 , 9, 5892-5905	3.3	30

170	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 65	51.1	30
169	Treatment of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2003 , 1, 10-8	6.9	29
168	Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. <i>World Journal of Gastroenterology</i> , 2007 , 13, 851-7	5.6	29
167	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021 , 73, 571-585	11.2	29
166	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018 , 68, 78-88	11.2	28
165	Is TRAIL hepatotoxic?. <i>Hepatology</i> , 2001 , 34, 3-6	11.2	28
164	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1085-1092	4	27
163	Decreasing mitochondrial fission prevents cholestatic liver injury. <i>Journal of Biological Chemistry</i> , 2014 , 289, 34074-88	5.4	27
162	Targeting PDGFR- β in Cholangiocarcinoma. <i>Liver International</i> , 2012 , 32, 400-9	7.9	27
161	Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. <i>Hepatology</i> , 2005 , 42, 1082-90	11.2	27
160	Deregulated methionine adenosyltransferase β , c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans. <i>Hepatology</i> , 2016 , 64, 439-55	11.2	27
159	Animal models of cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 982-992	6.9	27
158	Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. <i>Laboratory Investigation</i> , 2017 , 97, 1385-1396	5.9	26
157	A spotlight on cholangiocarcinoma. <i>Gastroenterology</i> , 2003 , 125, 1536-8	13.3	26
156	Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. <i>Hepatology</i> , 1995 , 21, 70-76	11.2	26
155	Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice. <i>Gastroenterology</i> , 2019 , 157, 210-226.e12	13.3	25
154	A Positive TGF- β -KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. <i>Neoplasia</i> , 2016 , 18, 371-86	6.4	25
153	High cell surface death receptor expression determines type I versus type II signaling. <i>Journal of Biological Chemistry</i> , 2011 , 286, 35823-35833	5.4	25

152	Cholestatic hepatocellular injury: what do we know and how should we proceed. <i>Journal of Hepatology</i> , 2005 , 42, 297-300	13.4	25
151	Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells. <i>PLoS ONE</i> , 2011 , 6, e18330	3.7	25
150	Current diagnostic and management options in perihilar cholangiocarcinoma. <i>Digestion</i> , 2014 , 89, 216-243.6	4.6	24
149	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 1028-364.5	4.5	24
148	"Will all liver transplantation patients eventually die from cancer?". <i>Journal of Hepatology</i> , 2006 , 44, 13-813.4	13.4	24
147	Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. <i>Hepatology</i> , 2002 , 35, 971-3	11.2	24
146	Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. <i>PLoS ONE</i> , 2014 , 9, e92124	3.7	23
145	Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. <i>Hepatology Research</i> , 2009 , 39, 805-13	5.1	23
144	Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, G709-16	5.1	23
143	TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity. <i>Hepatology Communications</i> , 2017 , 1, 648-662	6	22
142	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017 , 37, 159-174	7.3	21
141	Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. <i>Liver Transplantation</i> , 2013 , 19, 521-8	4.5	21
140	Caspase inhibitors for the treatment of hepatitis C. <i>Clinics in Liver Disease</i> , 2009 , 13, 467-75	4.6	21
139	Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. <i>Liver Transplantation</i> , 1998 , 4, 42-50		21
138	Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in cholecho-venous fistula rats. <i>American Journal of Physiology - Renal Physiology</i> , 2001 , 280, G805-11	5.1	21
137	Analysis of the Effectiveness of the Ad26.COVS Adenoviral Vector Vaccine for Preventing COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2132540	10.4	21
136	Metformin does not improve survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15750-5	5.6	21
135	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017 , 123, 81-89	6.4	20

134	Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. <i>Journal of the American College of Surgeons</i> , 2020 , 231, 98-110	4.4	19
133	The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2020 , 71, 741-748.2		19
132	YAP and the Hippo pathway in cholangiocarcinoma. <i>Journal of Gastroenterology</i> , 2019 , 54, 485-491	6.9	19
131	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021 , 74, 1145-1154	13.4	19
130	Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. <i>Journal of Hepatology</i> , 2011 , 54, 577-8	13.4	18
129	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017 , 8, 50542-50556	3.3	18
128	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S91-2	4.5	17
127	Liver Transplantation for Peri-hilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 2679-2685	3.3	17
126	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 742-748	3	16
125	Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2015 , 110, 200	0.7	16
124	Degradation of cIAPs contributes to hepatocyte lipoapoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 305, G611-9	5.1	16
123	Complete lysosomal disruption: a route to necrosis, not to the inflammasome. <i>Cell Cycle</i> , 2013 , 12, 1995	4.7	16
122	Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. <i>Liver International</i> , 2004 , 24, 687-95	7.9	16
121	Efflux of protons from acidic vesicles contributes to cytosolic acidification of hepatocytes during ATP depletion. <i>Hepatology</i> , 1991 , 14, 626-33	11.2	16
120	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. <i>Hepatology</i> , 2021 , 74, 281-295	11.2	16
119	Real-world effectiveness of Ad26.COVS adenoviral vector vaccine for COVID-19		16
118	Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified?. <i>Clinical Liver Disease</i> , 2016 , 8, 43-47	2.2	15
117	The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. <i>Journal of Biological Chemistry</i> , 2019 , 294, 18698-18713	5.4	15

116	Positron emission tomography scan for a hepatic mass. <i>Hepatology</i> , 2010 , 52, 2186-91	11.2	15
115	Targeting IL-6 in cholangiocarcinoma therapy. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2171-2	0.7	15
114	Liver transplantation for neuroendocrine tumors: progress and uncertainty. <i>Liver Transplantation</i> , 2004 , 10, 712-3	4.5	15
113	Diagnosis, Staging, and Treatment of Cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003 , 6, 105-112	2.5	15
112	Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations		15
111	Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1471-1478	4	15
110	Building a staircase to precision medicine for biliary tract cancer. <i>Nature Genetics</i> , 2015 , 47, 967-8	36.3	14
109	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 819-827	2.8	14
108	Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11. <i>American Journal of Physiology - Cell Physiology</i> , 2019 , 317, C788-C799	5.4	13
107	Acute Alcoholic Hepatitis: Natural History and Predictors of Mortality Using a Multicenter Prospective Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017 , 1, 37-48	3.1	13
106	Is ursodeoxycholate an antiapoptotic drug?. <i>Hepatology</i> , 1998 , 28, 1721-3	11.2	13
105	Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. <i>Journal of Hepatology</i> , 2008 , 49, 160-2	13.4	13
104	Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). <i>ELife</i> , 2020 , 9,	8.9	13
103	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021 , 161, 1475-1486	13.3	13
102	IQGAP1 promotes CXCR4 chemokine receptor function and trafficking via EEA-1+ endosomes. <i>Journal of Cell Biology</i> , 2015 , 210, 257-72	7.3	12
101	Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis. <i>Hepatology</i> , 2020 , 72, 1013-1028	11.2	12
100	Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma. <i>Hepatology</i> , 2020 , 72, 940-948	11.2	12
99	Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 271-5	2.7	11

98	Lack of metabolic effects of cholecystokinin on hepatocytes. <i>Hepatology</i> , 1990 , 12, 301-5	11.2	11
97	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021 , 73, 1868-1881	11.2	11
96	Emerging pharmacologic therapies for primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , 2017 , 33, 149-157	3	10
95	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. <i>JHEP Reports</i> , 2020 , 2, 100068	10.3	10
94	Liver Matrix in Benign and Malignant Biliary Tract Disease. <i>Seminars in Liver Disease</i> , 2020 , 40, 282-297	7.3	10
93	Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. <i>Cell Death and Disease</i> , 2020 , 11, 80	9.8	10
92	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. <i>Journal of Gastroenterology</i> , 2020 , 55, 523-532	6.9	10
91	Apoptosis and the liver: relevance for the hepato-biliary-pancreatic surgeon. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998 , 5, 409-15		10
90	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1576-1583.e1	6.9	10
89	Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration. <i>Current Eye Research</i> , 2020 , 45, 726-732	2.9	10
88	Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. <i>Annals of Surgery</i> , 2021 , 274, 780-788	7.8	10
87	Augmented Curation of Clinical Notes from a Massive EHR System Reveals Symptoms of Impending COVID-19 Diagnosis		9
86	Proapoptotic signaling induced by deletion of receptor-interacting kinase 1 and TNF receptor-associated factor 2 results in liver carcinogenesis. <i>Hepatology</i> , 2017 , 66, 983-985	11.2	8
85	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2018 , 68, 1228-1238	13.4	8
84	Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity 2020 ,		8
83	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2021 , 1	4.3	8
82	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. <i>Nature Cancer</i> , 2022 , 3, 386-401	15.4	8
81	A novel, minimally invasive technique for management of peristomal varices. <i>Hepatology</i> , 2016 , 63, 1398-1400	4.0	7

80	Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. <i>Cell Death and Disease</i> , 2017 , 8, e2535	9.8	7
79	Liver transplantation for intrahepatic cholangiocarcinoma--AuthorsPreply. <i>Lancet, The</i> , 2014 , 384, 1182-340	4.0	7
78	Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. <i>Transplant International</i> , 2015 , 28, 1383-91	3	7
77	Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 1908-17	4	7
76	The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. <i>Frontiers in Medicine</i> , 2020 , 7, 115	4.9	6
75	Localized hepatocellular carcinoma: therapeutic options. <i>Current Gastroenterology Reports</i> , 2000 , 2, 72-84	4.5	6
74	Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection 1994 , 19, 925		6
73	The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies. <i>Gene Expression</i> , 2020 , 20, 67-74	3.4	6
72	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA vaccines for COVID-19 from Moderna and Pfizer/BioNtech		6
71	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. <i>Liver Transplantation</i> , 2020 , 26, 549-563	4.5	5
70	Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. <i>Hepatology Research</i> , 2010 , 40, 701-10	5.1	5
69	Liver transplantation for non-hepatocellular carcinoma malignancies. <i>Liver Transplantation</i> , 2010 , 16, S22-S25	4.5	5
68	Cholangiocarcinoma: preventing invasion as anti-cancer strategy. <i>Journal of Hepatology</i> , 2003 , 38, 671-313.4	13.4	5
67	Tumors of the Bile Ducts, Gallbladder, and Ampulla 2010 , 1171-1184.e3		5
66	Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know. <i>Clinics in Liver Disease</i> , 2017 , 21, 725-737	4.6	5
65	Liver capsule: Cholangiocarcinoma (CCA). <i>Hepatology</i> , 2016 , 63, 1356	11.2	5
64	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4 Mouse. <i>American Journal of Pathology</i> , 2020 , 190, 1284-1297	5.8	5
63	Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. <i>Clinical Transplantation</i> , 2017 , 31, e13023	3.8	4

62	Liver transplantation for cholangiocarcinoma. <i>Liver Transplantation</i> , 2015 , 21 Suppl 1, S32-3	4.5	4
61	Yes, hepatocellular cancer does occur in primary biliary cirrhosis. <i>Liver Transplantation</i> , 2002 , 8, 570-1	4.5	4
60	Keratin, fas, and cryptogenic liver failure. <i>Liver Transplantation</i> , 2002 , 8, 1195-7	4.5	4
59	Impact of tri-modality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis. <i>Gastrointestinal Endoscopy</i> , 2021 ,	5.2	4
58	Plasma IL-6 Levels following Corticosteroid Therapy as an Indicator of ICU Length of Stay in Critically ill COVID-19 Patients		4
57	Cerebral venous sinus thrombosis (CVST) is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state US health system		4
56	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021 , 74, 2622-2632	11.2	4
55	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017 , 66, 4-5	19.2	3
54	Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 417-418	18.8	3
53	Reply. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 265-266	7.9	3
52	Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death. <i>Molecular Imaging and Biology</i> , 2020 , 22, 1310-1323	3.8	3
51	Treatment endpoints for advanced cholangiocarcinoma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004 , 1, 4-5		3
50	Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 319, G333-G344	5.1	3
49	Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation. <i>Cancers</i> , 2020 , 12,	6.6	3
48	Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. <i>Biochemistry</i> , 2020 , 59, 3856-3868	3.2	3
47	PPAR agonists for primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 693-698	6.8	2
46	Chemoembolization as a bridge to transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2001 , 7, 998	4.5	2
45	Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-11	6.4	2

44	The Death Receptor Pathway 2009 , 119-150		2
43	XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent and Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. <i>Frontiers in Physiology</i> , 2021 , 12, 664222	4.6	2
42	Nonalcoholic Steatohepatitis Promoting Kinases. <i>Seminars in Liver Disease</i> , 2020 , 40, 346-357	7.3	1
41	Hepatocyte Apoptosis 2020 , 195-205		1
40	The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 72, 1139-1141	11.2	1
39	Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. <i>Hepatology</i> , 2018 , 68, 2428-2430	11.2	1
38	Presentation of the Julius M. Friedenwald Medal to Nicholas F. LaRusso, MD. <i>Gastroenterology</i> , 2014 , 146, 1813-7	13.3	1
37	Mechanisms of Liver Injury 2017 , 200-217		1
36	AuthorsResponse to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. <i>Gut</i> , 2015 , 64, 522	19.2	1
35	Addressing unmet clinical needs: FISHing for bile duct cancer. <i>Cancer Cytopathology</i> , 2014 , 122, 789-90	3.9	1
34	Current status of liver transplantation for hilar cholangiocarcinoma. <i>Current Opinion in Organ Transplantation</i> , 2007 , 12, 215-219	2.5	1
33	Dying in Fas traffic. <i>Hepatology</i> , 2000 , 32, 439-40	11.2	1
32	Targeted use of siRNA in animal models of hepatic damage: an innovative therapy for acute liver failure. <i>Journal of Hepatology</i> , 2003 , 39, 883-5	13.4	1
31	High-Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. <i>Hepatology Communications</i> , 2021 ,	6	1
30	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. <i>Transplantation Direct</i> , 2021 , 7, e635	2.3	1
29	Hepatocyte Lethal and Nonlethal Lipotoxic Injury 2017 , 105-117		1
28	Liver Cell Death. <i>Molecular Pathology Library</i> , 2010 , 373-387		1
27	Liver transplantation for cholangiocarcinoma and other neoplastic diseases 2012 , 1712-1721.e1		1

26	The Two Faces of Relaxin in Cancer: Antitumor or Protumor?. <i>Hepatology</i> , 2020 , 71, 1117-1119	11.2	1
25	Transforming the practice of medicine through team science. <i>Health Research Policy and Systems</i> , 2020 , 18, 104	3.7	1
24	Female-male differences in COVID vaccine adverse events have precedence in seasonal flu shots: a potential link to sex-associated baseline gene expression patterns		1
23	REPLY. <i>Hepatology</i> , 2021 , 74, 535-536	11.2	1
22	Fatty liver progression and carcinogenesis: Beware of pathogenic T'cells.. <i>Med</i> , 2021 , 2, 453-455	31.7	1
21	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021 , 5, 1448-1459	6	1
20	Hedgehog Signaling Modulates Interleukin-33-Dependent Extrahepatic Bile Duct Cell Proliferation in Mice. <i>Hepatology Communications</i> , 2019 , 3, 277-292	6	1
19	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis 2022 , 1, 287-295		0
18	Cholangiocarcinoma: Disease Pathogenesis and New Treatment Paradigms 2017 , 219-228		
17	Endoscopic Ultrasound in the Diagnosis of Hepatobiliary Malignancy 2017 , 229-244		
16	Regulation of Cell Death in the Gastrointestinal Tract 231-239		
15	Mechanisms of Liver Injury 2011 , 216-231		
14	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2010 , 52, 394-395	11.2	
13	The Fas/FasL Signaling Pathway 2005 , 129-138		
12	The Death Receptor Family and the Extrinsic Pathway 2003 , 67-84		
11	The death receptor TRAIL in cancer cell apoptosis. <i>Annals of Cancer Research and Therapy</i> , 2005 , 13, 1-10	0.2	
10	Surgical Treatment of Primary Sclerosing Cholangitis 2019 , 1378-1385		
9	Fas/FasL 203-213		

- 8 Liver transplantation for nonhepatocellular malignant disease **2017**, 1791-1800.e2
- 7 Fas/FasL **2010**, 179-188
- 6 Genetics and Epidemiology of Cholangiocarcinoma **2010**, 75-99
- 5 REPLY. *Hepatology*, **2020**, 72, 362-363 11.2
- 4 Reply. *Hepatology*, **2020**, 72, 364-365 11.2
- 3 Transplantation for the Management of Malignancy **2021**, 74-81
- 2 Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y est[ustificada?. *Clinical Liver Disease*, **2016**, 8, S20-S24 2.2
- 1 The Difference a Decade Makes. *Hepatology*, **2021**, 73 Suppl 1, 1-3 11.2